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ABSTRACT
Peripheral blood is used almost exclusively as the source of hematopoietic cells for autografting, but the best
source of cells for allografting is the subject of considerable discussion and debate. Randomized studies
comparing unstimulated bone marrow with G-CSF–mobilized peripheral blood in the sibling allogeneic setting
have indicated a trend to more chronic graft-versus-host disease in peripheral blood recipients. However,
whether the use of G-CSF–mobilized peripheral blood cells leads to more acute graft-versus-host disease is
uncertain. Adults undergoing sibling allografting appear to benefit in terms of improved disease-free survival
or improved overall survival with the use of G-CSF–mobilized peripheral blood. It is not clear, however,
whether these benefits also extend to children or those undergoing matched unrelated transplantation.
© 2003 American Society for Blood and Marrow Transplantation
KEY WORDS
Bone marrow transplantation ● Peripheral blood transplantation ● Allogeneici
g
t
s
o
e
a
f
w
A
a
s
c
w
d
p
n
e
c
a
aNTRODUCTION
The preferred source of progenitor cells for high-
ose therapy and hematopoietic stem cell transplan-
ation has changed in the last 2 decades. Traditionally,
ells harvested directly from bone marrow in the iliac
rests were used for both autologous and allogeneic
ransplantation.
Progenitor cells capable of re-establishing hema-
opoiesis after myeloablative therapy are present in
ow concentrations in blood, but the number of
pheresis procedures required for a satisfactory graft
akes collection from unstimulated blood impracti-
al. However, the concentration of peripheral blood
rogenitor cells increases after the administration of
ecombinant growth factors such as granulocyte col-
ny-stimulating factor (G-CSF) or granulocyte-mac-
ophage colony-stimulating factor alone or after che-
otherapy, allowing collection of an adequate graft
ith only 1 apheresis procedure or a few apheresis
rocedures. Autologous peripheral blood harvesting
y apheresis has permitted the collection of large
umbers of progenitor cells, and phase II studies and
andomized trials [1,2] have demonstrated faster he-
atologic recovery compared with marrow autograft- v
B&MTng. Peripheral blood autografting has also facilitated
raft manipulations such as CD34 cell selection and
umor cell purging, which had been difﬁcult with the
maller number of progenitor cells collected by autol-
gous marrow harvesting. For these reasons, periph-
ral blood has almost completely replaced marrow in
utologous transplantation, and marrow is used only
or patients in whom mobilization is poor or those
ho cannot tolerate apheresis.
LLOGENEIC PERIPHERAL BLOOD TRANSPLANTATION
Peripheral blood as a source of progenitor cells for
llografting was initially overlooked for 2 major rea-
ons. First, compared with marrow, peripheral blood
ontains approximately 10-fold more T lymphocytes,
hich are the principal mediators of graft-versus-host
isease (GVHD). In marrow allografting, T-cell de-
letion studies had shown a correlation between the
umber of T lymphocytes in the allograft and the
xtent and severity of GVHD. Second, there were
oncerns about the risks to healthy donors of both
dministering recombinant growth factors and
pheresis, including uncertainty about whether centraloi:10.1016/j.bbmt.2003.08.012enous catheters would be required.
669
In 1995, 3 pivotal studies [3-5] demonstrated the
safety and feasibility of using G-CSF–mobilized pe-
ripheral blood allografts. Patients experienced prompt
hematologic recovery with an incidence of GVHD
similar to that described in marrow recipients. In
addition, no serious short-term complications of G-
CSF–mobilized peripheral blood harvesting were
noted among the healthy donors.
A retrospective study of HLA-identical sibling do-
nor transplants that compared outcome in recipients
of either peripheral blood (n  288) or marrow (n 
536) allografts [6] demonstrated more rapid neutro-
phil and platelet recovery among those who received
peripheral blood. Although there was no difference in
the incidence of grade II to IV acute GVHD, chronic
GVHD was more common in peripheral blood recip-
ients (65% versus 53%; P  .02). Treatment-related
mortality was lower and disease-free survival higher
among peripheral blood recipients who had more ad-
vanced disease; no difference was shown in those with
early disease.
RANDOMIZED TRIALS OF ALLOGENEIC PERIPHERAL
BLOOD TRANSPLANTATION
Direct comparisons of peripheral blood and mar-
row in allogeneic sibling donor transplantation have
been reported in at least 8 randomized trials [7-14].
The results from the 4 largest trials [9,12-14], which
included 829 evaluable patients, may be summarized
as follows.
Hematologic Recovery
Neutrophil and platelet recovery was faster among
peripheral blood allograft recipients. In some trials,
fewer red blood cell and platelet transfusions and
shorter hospitalizations were also reported.
Acute GVHD
Three [9,12,13] of the 4 trials found no difference
in the incidence or severity of acute GVHD among
peripheral blood and marrow recipients. In contrast,
the largest trial [14] described a statistically signiﬁ-
cantly higher incidence of grade II to IV acute GVHD
in peripheral blood recipients (52% versus 39%; P 
.01). Patients in this study did not receive day 11
methotrexate, whereas those in 2 of the other 3 studies
did, which may account for this difference.
Chronic GVHD
An increase (statistically signiﬁcant or a trend) in
the incidence of overall and extensive chronic GVHD
was demonstrated in recipients of peripheral blood
allografts. A meta-analysis of published reports [15]
that included randomized trials, registry data, and case
series has conﬁrmed this observation. However, al-
though more chronic GVHD with peripheral blood
allografting seems certain, the magnitude of this ob-
servation and its effect on relapse, survival, and recip-
ients’ quality of life are less clear. Furthermore,
chronic GVHD after peripheral blood allografting
may be qualitatively different from that after marrow
allografting, and further studies that include long-
term follow-up of patients in the randomized trials
will be important.
Survival
Only 1 trial [13] demonstrated a beneﬁt in overall
survival among peripheral blood recipients (68% ver-
sus 60% at 30 months; P  .04). Bensinger et al. [12]
reported a trend toward better overall survival of sim-
ilar magnitude among peripheral blood recipients
(66% versus 54% at 24 months; P  .06), whereas the
2 European studies [9,14] noted no difference.
Improved overall survival in the Canadian trial
[13] was due to lower treatment-related mortality in
peripheral blood recipients. It is interesting to note
that this beneﬁt was realized early (before day 30) and
continued beyond day 100. It seems likely that faster
hematologic recovery and more rapid and complete
early [16] and later [17,18] immunologic reconstitu-
tion contribute to lower treatment-related mortality
of peripheral blood recipients.
Although subgroup analyses of randomized stud-
ies are problematic because of power limitations and
imbalances of prognostic factors between groups, both
North American studies [12,13] demonstrated a sur-
vival beneﬁt of peripheral blood allografting only in
patients with advanced disease (acute myelogenous
leukemia beyond ﬁrst remission, chronic myelogenous
leukemia beyond the ﬁrst chronic phase, and myelo-
dysplastic syndrome with excess blasts). Such patients
may derive greater beneﬁt from the faster hematologic
and immunologic recovery afforded by peripheral
blood transplantation. Alternatively, peripheral blood
allografts may exert a more potent antitumor effect,
thus beneﬁting patients with advanced disease, al-
though this hypothesis remains unsubstantiated. Both
European studies [9,14] included predominantly pa-
tients with early disease, possibly accounting for the
absence of a survival beneﬁt of peripheral blood al-
lografting.
COLLECTION PROTOCOLS
The dose of G-CSF administered to donors dif-
fered signiﬁcantly in the 4 trials (Table 1). G-CSF
increases the number of CD34 progenitor cells in
the peripheral blood but also affects T lymphocytes,
dendritic cells, and natural killer cells, as well as other
cellular constituents of the allograft. G-CSF–mobi-
lized peripheral blood allografts contain substantially
Couban and Barnett
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more monocytes, natural killer cells, and dendritic
cells than marrow [17,19,20], and G-CSF directs T
lymphocytes to a T-helper type 2 phenotype that
secretes interleukin-4 and interleukin-10 [21]. Differ-
ences in the methodology of progenitor cell mobili-
zation with G-CSF and peripheral blood collection
may lead to substantial quantitative and qualitative
differences in the peripheral blood allograft between
studies that is not accounted for solely by CD34 cell
and T-lymphocyte quantitation. For example, the 3-
to 4-fold variation in G-CSF dose administered to
donors may have affected the extent of polarization of
T-helper cells in the allograft. Similarly, an allograft
collected in 1 day would necessarily be different from
an allograft collected over 2 days, even if both con-
tained a similar number of CD34 cells. More sophis-
ticated characterization of the allograft with compar-
ison of different collection strategies and further study
of immune recovery after transplantation may lead to
improved outcomes after peripheral blood allograft-
ing.
UNRELATED DONOR ALLOGENEIC TRANSPLANTATION
The safety and feasibility of peripheral blood al-
lografting with sibling donors has led to interest in its
application in the unrelated donor setting. Because
GVHD is the major cause of morbidity and mortality
in unrelated allogeneic transplantation, the observa-
tions of more acute GVHD disease in the European
Bone Marrow Transplantation Group study [14] and
more chronic GVHD in all randomized trials have
raised concerns about unrelated donor transplantation
with peripheral blood allografts. However, matched
cohort comparisons of unrelated marrow and periph-
eral blood transplantation [22,23] reported faster he-
matologic recovery among peripheral blood recipi-
ents, with no difference in either acute or chronic
GVHD or survival.
While results of randomized trials have been
pending, the use of peripheral blood allografts in un-
related transplantation has varied among transplant
centers and countries. Some have advocated unrelated
peripheral blood allografts for diseases in which the
risk of relapse is high and marrow allografts in diseases
such as chronic-phase chromic myelogenous leuke-
mia, in which the risk of relapse is relatively low.
However, the beneﬁt of chronic GVHD in reducing
the risk of relapse has yet to be demonstrated in
peripheral blood transplantation, and prospective con-
ﬁrmation of this treatment strategy is required.
Some registries of unrelated marrow donors have
permitted the collection of allografts from the periph-
eral blood, whereas others have not. Transplant cen-
ters may request a peripheral blood or marrow allo-
graft, but the collection center and wishes of the
volunteer donor also determine which product is ul-
timately collected. Despite the absence of deﬁnitive
data comparing unrelated marrow and peripheral
blood transplantation, the use of peripheral blood al-
lografts for unrelated transplantation is increasing in
Europe and North America, and the window of op-
portunity within which to complete a randomized trial
may be closing.
DONOR CONSIDERATIONS
Marrow harvesting from healthy donors is gener-
ally safe and well tolerated, and serious risks are lim-
ited mainly to the complications of general anesthesia.
Peripheral blood donors must receive a recombinant
growth factor for several days followed by 1 or more
apheresis procedures. Administration of growth fac-
tors such as G-CSF to donors was initially a major
safety concern in peripheral blood allografting. G-
CSF causes donors to experience bone pain, myalgias,
arthralgias, and malaise [24]. It also leads to leukocy-
tosis, thrombocytopenia, and increases of alkaline
phosphatase, lactate dehydrogenase, uric acid, alanine
aminotransferase, -glutamyl transpeptidase, pro-
thrombin, thrombin/antithrombin complexes, and d-
dimer [25]. Although these common effects are usually
transient, rare but more serious medical events, in-
cluding myocardial infarction and stroke [26,27], have
been reported. There have also been cases of sponta-
neous splenic rupture requiring emergency splenec-
tomy after G-CSF administration to healthy donors
[28,29]. Careful follow-up of donors who receive G-
CSF is essential to determine whether there are seri-
ous long-term effects of this practice.
Table 1. Collection Protocols, Target CD34 Cell Dose, and CD34 Cell and T-Lymphocyte Content (per Kilogram of Recipient’s Weight) of
Peripheral Blood (PB) Allografts in 4 Randomized Comparisons of Allogeneic Marrow and Peripheral Blood
Study
G-CSF
Dose
(g/kg/d)
Days of
G-CSF
Number of
Aphereses, Median
(Range)
Target PB
CD34
Cell Dose
Actual PB CD34
Cell Dose, Median
(Range)
Actual PB T-Cell
Dose, Median
(Range)
Schmitz et al. [14] 10 4 1 (1-3) 4  106 5.8  106 (1.5-68.3) 300  106 (16-2123)
Couban et al. [13] 5 4 2 (1-2)* 2.5  106 6.4  106 (0.7-32) 370  106 (120-3080)
Bensinger et al. [12] 16 5 1 (1-4) 5  106 7.3  106 (1.0-29.8) 279  106 (143-788)
Blaise et al. [9] 10 5 2 (1-3) 4  106 6.6  106 (1.5-19.2) 356  106 (131-754)
*If the target CD34 cell dose was not achieved after 2 aphereses, the protocol called for a marrow harvest to supplement the PB collection.
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ALLOGENEIC G-CSF–STIMULATED MARROW
TRANSPLANTATION
The use of autologous and allogeneic progenitor
cells collected from peripheral blood leads to faster
hematologic recovery because more CD34 cells are
obtained. This approach also leads to the collection of
10-fold more T lymphocytes, which may explain the
higher incidence of chronic GVHD after peripheral
blood allografting. It is possible that treatment of a
donor with G-CSF before marrow harvest may also
allow collection of more CD34 progenitor cells
compared with unstimulated marrow without the
large number of T lymphocytes that accompany pe-
ripheral blood collection. Several investigators have
demonstrated the safety and feasibility of this strategy
[30-32]. A randomized comparison of G-CSF–mobi-
lized peripheral blood and G-CSF–stimulated marrow
allografts closed early because more overall (90% ver-
sus 47%; P  .02) and extensive (80% versus 22%;
P  .02) chronic GVHD was seen in peripheral blood
compared with G-CSF–stimulated marrow recipients
[33]. No difference in overall survival was observed
among the 57 evaluable patients, and further studies of
this approach are warranted.
CONCLUSIONS
The use of G-CSF–mobilized peripheral blood
allografts is a safe and feasible alternative to unstimu-
lated marrow. In matched sibling donor allogeneic
transplantation, peripheral blood allografts lead to
faster hematologic recovery and may result in less
blood product use and shorter hospitalizations. De-
spite no apparent increase in acute GVHD, peripheral
blood allografting is associated with more chronic
GVHD, and the effect of this on survival, relapse, and
the recipients’ quality of life remains to be deter-
mined.
In the absence of evidence from randomized trials,
bone marrow remains the standard allograft for unre-
lated transplantation, although peripheral blood may
be a reasonable alternative. Further studies of the
long-term outcome of allogeneic peripheral blood
transplantation are needed to deﬁne the consequences
of increased chronic GVHD. In addition, randomized
trials of mobilized blood allografts in unrelated trans-
plantation and in children, as well as further evalua-
tion of stimulated marrow allografts, are required.
Finally, as the components of the allograft are better
characterized and understood, it should be possible to
deﬁne optimal mobilization, stimulation, and collec-
tion strategies.
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